Lumanity Executive and Leadership Team

Andrew Dreyfus, the President & Chief Executive Officer at Lumanity, directs the overarching corporate strategy to optimize medical access across global markets. By aligning internal expertise with the evolving needs of pharmaceutical and biotech partners, the President & Chief Executive Officer ensures that data-driven insights translate into successful commercialization outcomes. This leadership role involves constant collaboration with the Board to maintain a competitive edge in regulatory and commercial affairs. Andrew Dreyfus maintains a sharp focus on scaling operations across North America, Europe, and Asia to support the company mission. Through the integration of medical and commercial intelligence, the President & Chief Executive Officer drives sustainable growth and ensures that medical advances reach patients efficiently. By fostering a culture of decisive action, the executive secures the long-term market position of the firm while delivering value to providers, payers, and regulators worldwide.

Michael Madden, the Chief Financial Officer & Chief Operating Officer at Lumanity, manages the financial health and operational infrastructure required to support global expansion. Overseeing fiscal planning and internal resource allocation, the Chief Financial Officer & Chief Operating Officer ensures that the firm maintains the agility necessary to conduct work in over 50 countries. This dual-function role requires constant synchronization with executive leadership to optimize the delivery of evidence-based solutions for biotech clients. Michael Madden architects robust financial frameworks that support the company's ability to generate real-world insights and evidence. By streamlining operational workflows, the Chief Financial Officer & Chief Operating Officer enhances the efficiency of commercial brand launches and payer submissions. Through rigorous oversight of capital and operational assets, the executive sustains the firm's capacity to transform complex medical data into successful market outcomes for diverse global stakeholders.

Julie Munakata, the Global President, HEOR at Lumanity, leads the health economics and outcomes research division to demonstrate the value of medical products. By identifying the specific evidence required by payers and regulators, the Global President, HEOR ensures that pharmaceutical clients can justify product pricing and secure market access. This leadership position involves managing complex research projects that translate scientific data into compelling narratives for global stakeholders. Julie Munakata oversees the development of robust evidence packages that support sustainable commercial success. Through the application of incisive thinking, the Global President, HEOR enables the firm to provide actionable insights that empower patients and providers. By coordinating with international teams, the executive drives the expansion of research capabilities across key geographic regions. Ultimately, Munakata secures the firm's reputation as a leader in evidence generation and value demonstration within the competitive life sciences sector.

Stephen Weisman, the Global President at Lumanity, oversees the execution of commercial strategies and the delivery of transformative outcomes for international clients. By managing the integration of medical and regulatory affairs, the Global President ensures that product narratives remain relevant and impactful across diverse global markets. This role involves coordinating with cross-functional teams to enable successful development strategies and brand launches. Stephen Weisman drives the firm's mission to optimize access to medical advances by aligning commercial decisions with real-world evidence. Through the oversight of large-scale operations, the Global President maintains the quality and consistency of services provided to top pharmaceutical companies. By fostering strong relationships with key stakeholders, the executive supports the firm's growth in North America and beyond. Ultimately, Weisman ensures that the company consistently turns complex scientific aspirations into tangible market realities for patients and providers.

Robert Budreau, the President & Producer at Lumanity, directs the creative and production efforts required to translate complex science into compelling product narratives. By overseeing the development of high-impact campaigns, the President & Producer ensures that medical information resonates with target audiences and stakeholders. This leadership role involves bridging the gap between technical data and effective communication strategies to support successful brand launches. Robert Budreau manages the production lifecycle to ensure that all deliverables align with the firm's commitment to evidence-based insights. Through the application of creative expertise, the President & Producer enhances the visibility and market relevance of client products. By collaborating with commercial and medical teams, the executive ensures that every campaign reflects the value of the underlying medical advances. Ultimately, Budreau drives the firm's ability to deliver successful product campaigns that empower patients and providers to take timely, decisive action.

John Howley, the President, Communications (US) at Lumanity, manages the strategic communication initiatives that support commercial success within the North American market. By crafting narratives that translate complex medical data into clear, actionable insights, the President, Communications (US) ensures that pharmaceutical and biotech clients effectively reach their target audiences. This role involves overseeing the alignment of communication strategies with regulatory requirements and commercial goals. John Howley directs the development of messaging that demonstrates the value of medical products to payers, providers, and patients. Through the coordination of regional communication efforts, the President, Communications (US) strengthens the firm's market presence and supports successful brand launches. By leveraging deep industry experience, the executive ensures that all communications reflect the firm's commitment to incisive thinking. Ultimately, Howley drives the impact of client campaigns by ensuring that scientific evidence remains at the core of every message.

Christopher Evans, the President Patient-Centered Outcomes at Lumanity, leads the efforts to integrate patient perspectives into the development and commercialization of medical advances. By identifying the outcomes that matter most to patients, the President Patient-Centered Outcomes ensures that evidence generation reflects real-world needs and experiences. This leadership role involves managing research initiatives that translate patient data into actionable insights for pharmaceutical and biotech partners. Christopher Evans oversees the development of strategies that empower patients and providers to make informed decisions. Through the application of rigorous research methodologies, the President Patient-Centered Outcomes supports the firm's mission to optimize access to medical treatments. By collaborating with global teams, the executive ensures that patient-centered evidence informs commercial decisions and payer submissions. Ultimately, Evans drives the firm's commitment to delivering outcomes that improve the lives of patients while ensuring the sustainable success of medical products in the market.

Marissa Poli, the President at Lumanity, directs the strategic development and execution of commercial initiatives to support the firm's growth in key market segments. By overseeing the alignment of medical and commercial affairs, the President ensures that the company delivers transformative outcomes for its diverse client base. This leadership role involves managing cross-functional teams to optimize the delivery of evidence-based solutions and development strategies. Marissa Poli drives the firm's mission by fostering innovation in how medical advances are brought to market. Through the oversight of operational excellence, the President ensures that the company maintains its competitive edge in the pharmaceutical and biotech sectors. By collaborating with other executive leaders, the executive supports the firm's ability to conduct work across multiple regions and countries. Ultimately, Poli secures the firm's capacity to turn complex situations into successful commercial realities for patients, providers, and payers.